The Relentless Focus on Amyloid Clearance for Later Stage Alzheimer’s Disease is Disintegrating

In hindsight, the Alzheimer’s research and development community of the past fifteen years or so has been a strange place. The vast, overwhelming majority of investment has gone towards attempts to clear amyloid-β in later stage Alzheimer’s disease, largely via immunotherapies. This strategy has failed, over and again, long past the point at which it was defensible to blame that failure on the challenging nature of the underlying projects to first make immunotherapies work at all, and then to make them work in the brain. Enormous sums were spent on repeated attempts to clear amyloid-β even as the research community was settling on the consensus that aggregation of amyloid-β is a feature of early Alzheimer’s. It only causes mild cognitive impairment on its own

From https://www.fightaging.org/archives/2019/03/the-relentless-focus-on-amyloid-clearance-for-later-stage-alzheimers-disease-is-disintegrating/

from
https://healthnews010.wordpress.com/2019/03/26/the-relentless-focus-on-amyloid-clearance-for-later-stage-alzheimers-disease-is-disintegrating/

from https://karlfletcher.blogspot.com/2019/03/the-relentless-focus-on-amyloid.html

from
https://karlfletcher1.tumblr.com/post/183715574463